The highly significant co-occurrence of TP53 and FLG2 gene mutations was observed in ovarian cancer, but no study has confirmed the role of the co-mutation of these two genes ( 12 , 13 ).
← all excerpts
Comprehensive bioinformatics analysis of co-mutation of <i>FLG2</i> and <i>TP53</i> reveals prognostic effect and influences on the immune infiltration in ovarian serous cystadenocarcinoma.
1
—
—